Michaeli J, Lebedev Y B, Richon V M, Chen Z X, Marks P A, Rifkind R A
DeWitt Wallace Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York.
Mol Cell Biol. 1990 Jul;10(7):3535-40. doi: 10.1128/mcb.10.7.3535-3540.1990.
Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of murine erythroleukemia cells (MELC). Commitment, the irreversible initiation of the program of terminal-cell differentiation, is first detected in HMBA-sensitive DS19-SC9 MELC in culture after 10 to 12 h of exposure to HMBA. Vincristine (VC)-resistant MELC derived from the DS19-SC9 MELC line display increased sensitivity to HMBA and become committed with little or no latent period. In the present study, we showed that the MELC line R1, which is resistant to HMBA-mediated differentiation, became sensitive to inducer if selected for a low level of VC resistance (less than 10 ng of VC per ml). Four independently derived VC-resistant cell lines from HMBA-resistant R1 cells, designated R1[VCR]a to R1[VCR]d, acquired sensitivity to HMBA and the accelerated kinetics of commitment that are characteristic of VC-resistant MELC derived from the parental DS19-SC9 cells. The calcium channel blocker verapamil suppresses the VC resistance of R1[VCR] cells but does not alter the accelerated response to HMBA. In R1[VCR] cells there was no detectable increase in the level of the 140-kilodalton P-glycoprotein. Transient inhibition of protein synthesis during the latent period delays inducer-mediated commitment of VC-sensitive DS19-SC9 MELC but does not alter the accelerated commitment kinetics of R1[VCR]a cells. Previously, we have reported evidence that protein kinase C beta (PKC beta) plays a role in HMBA-induced MELC differentiation and that compared with DS19-SC9 cells, R1 cells have a relatively low level and R1[VCR]a cells have a high level of PKC beta. These findings suggest that (i) acquisition of VC resistance overcomes the block acquired by R1 cells to HMBA-mediated differentiation; (ii) the accelerated kinetics of HMBA-induced commitment of VC-resistant MELC is not dependent on the verapamil-sensitive transport channel that is responsible, at least in part, for resistance to VC; (iii) in VC-resistant MELC, there is constitutive expression or accumulation of a protein required for HMBA-induced differentiation; and (iv) an elevated level of PKC beta activity may play a role in the altered response of R1[VCR] and other VC-resistant MELC to HMBA.
六亚甲基双乙酰胺(HMBA)是鼠红细胞白血病细胞(MELC)分化的一种有效诱导剂。细胞定向分化,即终末细胞分化程序的不可逆启动,在培养的对HMBA敏感的DS19-SC9 MELC中,在暴露于HMBA 10至12小时后首次被检测到。源自DS19-SC9 MELC系的长春新碱(VC)耐药MELC对HMBA的敏感性增加,并且在很少或没有潜伏期的情况下就发生定向分化。在本研究中,我们发现对HMBA介导的分化具有抗性的MELC系R1,如果选择对低水平VC耐药(每毫升少于10纳克VC),则会对诱导剂变得敏感。从对HMBA耐药的R1细胞中独立获得的四个VC耐药细胞系,命名为R1[VCR]a至R1[VCR]d,获得了对HMBA的敏感性以及快速的定向分化动力学,这是源自亲本DS19-SC9细胞的VC耐药MELC的特征。钙通道阻滞剂维拉帕米可抑制R1[VCR]细胞对VC的耐药性,但不会改变对HMBA的快速反应。在R1[VCR]细胞中,未检测到140千道尔顿P-糖蛋白水平的增加。在潜伏期短暂抑制蛋白质合成会延迟诱导剂介导的对VC敏感的DS19-SC9 MELC的定向分化,但不会改变R1[VCR]a细胞快速的定向分化动力学。此前,我们已报道有证据表明蛋白激酶Cβ(PKCβ)在HMBA诱导的MELC分化中起作用,并且与DS19-SC9细胞相比,R1细胞中PKCβ水平相对较低,而R1[VCR]a细胞中PKCβ水平较高。这些发现表明:(i)获得VC耐药性克服了R1细胞对HMBA介导的分化所获得的阻滞;(ii)HMBA诱导的VC耐药MELC定向分化的快速动力学不依赖于维拉帕米敏感的转运通道,该通道至少部分负责对VC的耐药性;(iii)在VC耐药MELC中,存在HMBA诱导分化所需蛋白质的组成性表达或积累;(iv)PKCβ活性水平升高可能在R1[VCR]和其他VC耐药MELC对HMBA的改变反应中起作用。